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Berkeley, Berkeley, CA 94720-3220, USAInterfacing gene delivery vehicles with biomaterials has the
potential to play a key role in diversifying gene transfer capabil-
ities, including localized, patterned, and controlled delivery.
However, strategies for modifying biomaterials to interact
with delivery vectors must be redesigned whenever new delivery
vehicles and applications are explored. We have developed a
vector-independent biomaterial platform capable of interact-
ing with various adeno-associated viral (AAV) serotypes. A
water-soluble, cysteine-tagged, recombinant protein version
of the recently discovered multi-AAV serotype receptor
(AAVR), referred to as cys-AAVR, was conjugated to malei-
mide-displaying polycaprolactone (PCL) materials using click
chemistry. The resulting cys-AAVR-PCL system bound to a
broad range of therapeutically relevant AAV serotypes, thereby
providing a platform capable of modulating the delivery of all
AAV serotypes. Intramuscular injection of cys-AAVR-PCL mi-
crospheres with bound AAV vectors resulted in localized and
sustained gene delivery as well as reduced spread to off-target
organs compared to a vector solution. This cys-AAVR-PCL sys-
tem is thus an effective approach for biomaterial-based AAV
gene delivery for a broad range of therapeutic applications.Received 28 August 2018; accepted 17 September 2019;
https://doi.org/10.1016/j.omtn.2019.09.015.
6These authors contributed equally to this work.
Correspondence: David V. Schaffer, Department of Chemical and Biomolecular
Engineering, University of California, Berkeley, Berkeley, CA 94720-3220.
E-mail: schaffer@berkeley.edu
Correspondence: Jae-Hyung Jang, Department of Chemical and Biomolecular
Engineering, Yonsei University, Seoul 120-749, Korea.
E-mail: j-jang@yonsei.ac.krINTRODUCTION
Adeno-associated virus (AAV)-based gene delivery vectors have
gained widespread attention due to their progressively stronger
record of safety and efﬁcacy in clinical trials,1–3 including hemophilia
B and A (using AAV8 and AAV5), spinal muscular atrophy (AAV9),
and lipoprotein lipase deﬁciency (AAV1).4–7 This record recently led
to two US Food and Drug Administration approvals of gene therapies
for the rare diseases Leber’s congenital amaurosis and spinal muscular
atrophy. However, numerous challenges remain in the ﬁeld, including
problems with delivery efﬁciency and controlled biodistribution. For
example, even local injections of AAV into tissues such as muscle or
CNS result in vector spread to distal tissues such as the liver,8 which
increases the risks of off-target side effects or immune responses.
Additionally, a burst of gene expression following the injection of
high doses of a vector risks toxicity,3 and alleviating such concerns
via multiple administrations of lower doses can increase medical costs432 Molecular Therapy: Nucleic Acids Vol. 18 December 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpand patients’ inconvenience.9 Thus, strategies to diversify the capabil-
ities of AAV-mediated gene delivery systems (i.e., localized, sustained,
and/or controlled delivery) may address these concerns and thereby
further boost therapeutic efﬁcacy.
Binding or adsorbing AAV vectors onto biomaterial surfaces and
locally administrating the resulting “composites” to a target tissue
or organ is an alternative strategy for overcoming limitations with
direct virus injection.10,11 For example, vector immobilization to a
biomaterial can reduce systemic spread or leakage while increasing
vector residence time in the target cellular microenvironment,
thereby potentially restricting gene expression to the injected re-
gion.12,13 Vector “loading” onto a biomaterial can be mediated by
either non-speciﬁc adsorption14–19 or speciﬁc afﬁnity binding.20,21
For example, we have bound vectors to the surfaces of materials
modiﬁed with adhesives or charged moieties, even in a spatially
dependent manner.15 Similarly, we have inserted a hexa-histidine af-
ﬁnity tag onto AAV for immobilization onto nickel-presenting sur-
faces,20 and, in other work, the insertion of an epitope onto the vector
has enabled antibody-mediated incorporation into a material.21
However, different therapeutic applications necessitate the use of
different AAV variants or serotypes2 (as evident from the range of
AAVs used in promising trials to date: AAV1, AAV2, AAV5,
AAV8, and AAV94–7) such that strategies for biomaterial immobili-
zation must be newly designed on demand to speciﬁcally incorporate
the chosen AAV vector. Moreover, altering AAV capsids to mediate
interactions with a biomaterial can alter their gene delivery proper-
ties, potentially negating the advantages of biomaterial-mediated
delivery. For all these reasons, a versatile system that can interactThe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Production of cys-AAVR Proteins
(A) Peptide sequence of hexa-histidine/cysteine-tagged
PKD1-5 domains (cys-AAVR), which possess a high
affinity for AAV vectors. (B) Reduction of transduction
efficiencies by AAV serotypes that interacted with free
cys-AAVR proteins (0.2 or 2 mM). The genomic MOIs of
each AAV vector were adjusted to obtain appreciable
levels of transduction efficiencies in HEK293T cells
(i.e., 1 X 105 for AAV1, -4, -5, -8, and -9 and 1  104 for
AAV2, -3, -6, and -r3.45). *p < 0.05. Error bars represent
SDs.
www.moleculartherapy.orgwith the majority of AAV serotypes and newly emerging engineered
variants would be impactful for biomaterial-mediated delivery.
Integrating components of glycans, which typically serve as initial
receptors for AAV cell binding, into biomaterials offers a means of
enabling AAV vector binding without altering viral capsids. For
example, column-immobilized heparin and mucin—which present
structures similar to those of heparan sulfate proteoglycan (HSPG)
and sialic acid moieties, which serve as primary receptors for
AAV222 and AAV5,23 respectively—have been used for afﬁnity bind-
ing of these serotypes.24 However, because different AAV variants
bind to alternate glycan receptors, different serotypes would necessi-
tate different designs. Alternatively, a receptor that interacts with all
of the AAV serotypes tested to date, denoted as the AAV receptor
(AAVR), was recently identiﬁed.25
Here, we have developed an AAVR-functionalized biomaterial
platform that can immobilize AAV vectors of various serotypes.
Speciﬁcally, a water-soluble, cysteine-tagged recombinant version
of the polycystic kidney disease (PKD) domains of AAVR protein,
referred to as cys-AAVR, was linked by click chemistry to polycap-
rolactone (PCL) surfaces. The resulting “serotype-independent” cys-
AAVR-PCL system demonstrated the versatile capacity to bind
multiple AAV serotypes as well as an engineered AAV variant.
Furthermore, the intramuscular injection of AAV-loaded biomate-
rials resulted in highly localized gene expression over extended
periods and considerably less spread to off-targets tissues, such as
liver and heart, compared to injection of a vector solution. Finally,
speciﬁc interactions of the cys-AAVR-PCL system with AAV vec-
tors enabled spatially patterned gene expression in vivo, corre-
sponding to the structural morphology of implanted PCL material.
By successfully integrating AAVR protein into biomaterials for the
ﬁrst time, this study offers new options for controlled AAV gene
delivery.
RESULTS
Production of cys-AAVR Capable of Simultaneously Interacting
with Multiple AAV Serotypes
A water-soluble, cysteine-tagged version of the AAVR ectodomain
(cys-AAVR) containing the AAV-binding region25 was designedfor conjugation to the surface of polyester-based biodegradable/
biocompatible PCL materials, which were formulated as either
microspheres or electrospun ﬁbrous matrices, to create a system for
immobilizing AAV (cys-AAVR-PCL), as schematically shown in
Figure 1A. The cys-AAVR was engineered with a hexa-histidine
and three cysteine residues at the N terminus of the PKD1 domain
to facilitate cys-AAVR protein puriﬁcation and act as functional
groups for biomaterial conjugation, respectively (Figure 1A). Rather
than conjugating via lysine amino groups along the protein’s native
sequence, which can in general interfere with protein function, termi-
nal cysteine thiols were selected as functional linkers.26 The resulting
histidine/cysteine-tagged AAVR protein was successfully expressed
and puriﬁed from E. coli, resulting in the predicted 55 kDa molecular
weight protein product (Figure S1).
The functionality of the cys-AAVR protein was assessed by testing its
interactions with multiple AAV serotypes and an engineered variant:
AAV1, -2, -3, -4, -5, -6, -8, and -9 and AAVr3.45 (a vector that was
engineered for high efﬁciency transduction of neural stem cells and
exhibits strong therapeutic potential27–31). Speciﬁcally, soluble
cys-AAVR protein was mixed with each vector (packaged with
cDNA encoding GFP), and the resulting solution was added to a
cell culture. The transduction by all the AAV/cys-AAVR mixtures
was signiﬁcantly reduced compared to free, naive AAV vector (i.e.,
only virus) (Figure 1B), presumably due to the competitive inhibition
of the binding of AAV to the cell surface AAVR.25 As observed in pre-
vious studies, which reported that AAV4’s infectious pathway does
not involve AAVR-mediated internalization,32 an exception was
that the inhibition of AAV4 infection required a signiﬁcantly higher
concentration of cys-AAVR (2.0 rather than 0.2 mM; p < 0.05), and
the inhibition was not always consistent. Therefore, we focused on se-
rotypes other than AAV4 for all subsequent analysis.
Conjugation of cys-AAVR onto PCL Systems
cys-AAVR was conjugated to the surface of PCL via thiol-maleimide
click chemistry. Two PCL material formats, microspheres (average
diameter = 22.0 ± 9.3 mm) and ﬁbrous structures (average ﬁber
diameter = 0.63 ± 0.23 mm), were formulated by water-oil emulsion
and an electrospinning process, respectively, prior to their surface
modiﬁcation (Figure 2A). Microsphere formulations have beenMolecular Therapy: Nucleic Acids Vol. 18 December 2019 433
Figure 2. Preparation and Characterization of cys-AAVR-PCL Surfaces
(A) Reaction scheme to generate PCL-NH2, PCL-click, and cys-AAVR-PCLmicrospheres. The SEM images in the top panel demonstrate the representative morphologies of
PCL microspheres (top) and electrospun fibrous matrices (bottom). The ester bonds within the repeated units of PCL chains reacted with 1,6-hexanediamine (HDA) to
generate amide bonds, consequently displaying primary amines on the PCL templates (PCL-NH2). The resulting templates were treated with sulfo-SMCC to attach mal-
eimide groups (PCL-click), which can, in turn, covalently react with the sulfhydryl groups on the cysteine chains of cys-AAVR. (B) FT-IR analysis of aminolyzed PCL (PCL-NH2)
and maleimide-displaying PCL (PCL-click) microspheres. (C) Quantity of exposed amines on PCL-NH2 microspheres, which was measured by ninhydrin assay. (D)
Quantification of cys-AAVR proteins that were conjugated to PCL-click microspheres. The quantity of cys-AAVR in the solution wasmeasured using a BCA assay kit, and the
percentage indicates the fraction of cys-AAVR that bound to the PCL-clickmicrospheres relative to its initial amount. Error bars in (C) and (D) represent SDs. (E) Visualization of
Alexa 594-tagged cys-AAVR proteins on PCL-click microspheres. The white dotted line illustrates the contour of a PCLmicrosphere. (F) Water contact angles on cys-AAVR-
PCL or non-modified PCL electrospun fibrous matrices at 0.5, 1, and 1.5 s. (G) Different behaviors of cys-AAVR-displaying PCL electrospun fibrous matrix (left) and
microspheres (right) in aqueous solution compared to those of non-modified naive PCL systems.
Molecular Therapy: Nucleic Acidswidely used as injectable carriers for surface-bound therapeutic
agents (e.g., cells, gene vectors, and drugs) at deﬁned locations.33–35
In addition, electrospun materials—generated in an electrospinner
via the application of an electrostatic force to a polymer solution to
generate nano-/micro-scaled polymeric threads of dimensions that
mimic the ﬁbrous morphologies of extracellular matrices (ECMs)—
can serve as physical supports for cells in gene therapy and tissue en-
gineering applications.36–38
As schematically illustrated in Figure 2A, maleimide groups were dis-
played from the surfaces of both the PCL formats to covalently react
with the sulfhydryl groups on the cysteine chains of cys-AAVR. First,
the PCL surfaces were prepared via 1,6-hexanediamine (HDA)-medi-434 Molecular Therapy: Nucleic Acids Vol. 18 December 2019ated amination, resulting in absorption peaks for primary amines at
3,329 and 1,566 cm1 (Figure 2B) that increased with the reaction
time to a plateau of approximately 12.0 pmol of amines per
PCL microsphere (Figure 2C). The amines were subsequently
reacted with sulfosuccinimidyl-4-(N-maleimidomethyl) cyclo-
hexane-1-carboxylate (sulfo-SMCC) to yield maleimides. Upon
adding the resulting maleimide-activated PCL microspheres (i.e.,
PCL-click) to a cys-AAVR solution, nearly all of the free cys-AAVR
was successfully captured onto the PCL surfaces, whereas, in contrast,
the majority of cys-AAVR remained in solution when non-function-
alized PCL microspheres were added (Figure 2D). Alexa-594-labeled
cys-AAVR was used to visualize its immobilization, and abundant
AAVR was observed on the PCL-click microsphere surface
Figure 3. Capacity of cys-AAVR-PCL Microspheres
to Capture Various AAV Serotypes
Various AAVs were incubated with cys-AAVR-PCL;
moreover, naive viral supernatant (black bars), superna-
tants depleted by non-modified PCL microspheres (gray),
or supernatants depleted with cys-AAVR-PCL (white)
were incubated with HEK293T cells. Incubation with
the cys-AAVR-functionalized microspheres uniformly
depleted the infectious AAV from the lysates. The volume
of cell lysates containing each AAV serotype was adjusted
to obtain the highest transduction efficiencies for each AAV-GFP vector, and the same volume was utilized for interacting with the non-modified or cys-AAVR-PCL mi-
crospheres. High viral quantities (i.e., MOI of 1  105) were used to interact with each PCL microsphere set. Transduction efficiencies obtained by non-bound AAV vectors
were normalized to those by virus only. *p < 0.05. Error bars represent SDs.
www.moleculartherapy.orgin contrast to the low ﬂuorescence on the non-modiﬁed PCL micro-
spheres (Figure 2E).
The cys-AAVR immobilization signiﬁcantly altered the properties
of the PCL-click surfaces, as assessed using electrospun ﬁbrous
surfaces, which are reasonably suited for water contact angle
analysis of surface hydrophobicity/hydrophilicity. Water droplets
promptly adhered to the cys-AAVR-PCL electrospun ﬁbrous
matrices, indicating the hydrophilic nature of the protein-modiﬁed
surface: 35 at 0.5 s, 23 at 1 s, and 0 at 1.5 s. In contrast, high
water-contact angles (138) were consistently maintained on the
non-modiﬁed PCL matrices (Figure 2F). As an alternate indicator,
cys-AAVR-PCL electrospun ﬁbers settled immediately to the bot-
tom of the aqueous solutions, whereas the non-modiﬁed hydro-
phobic PCL matrices ﬂoated on the water surface (Figure 2G).
Finally, cys-AAVR-PCL microspheres could be homogeneously
dispersed in water for extended times, whereas an apparent phase
separation was observed when non-modiﬁed PCL microspheres
were present in the aqueous solutions (Figure 2G). In addition to
indicating the occurrence of cys-AAVR immobilization, this tran-
sition of PCL into a hydrophilic surface is important for facilitating
interactions with the AAV vectors suspended in the aqueous
solution.
Viral Binding onto cys-AAVR-PCL Systems
The capacity of the cys-AAVR system to speciﬁcally capture AAV
vectors was initially examined by comparing AAV9 binding to the
surfaces of PCL microspheres for different modes (Figure S2): (1)
different binding mechanisms (i.e., non-speciﬁc adsorption versus
speciﬁc interaction), (2) different viral purity (puriﬁed vectors
versus vectors in crude lysates), and (3) different afﬁnity to cys-
AAVR in different states (vector binding onto adhered cys-
AAVR versus free cys-AAVR). Approximately 2-fold increases in
speciﬁc interactions of AAV9 on the cys-AAVR-PCL microspheres
occurred compared to non-speciﬁc adsorption on the non-modi-
ﬁed PCL microspheres (Figure S2A). In addition, interactions of
the cys-AAVR with AAV vectors were enhanced when viral vec-
tors were previously puriﬁed rather than in crude lysates (Fig-
ure S2B). Finally, even in the presence of free cys-AAVR proteins,
the cys-AAVR-PCL microspheres demonstrated a signiﬁcantly
improved ability to capture AAV compared to the non-modiﬁedPCL microspheres (Figure S2C). These results conﬁrm speciﬁc in-
teractions of cys-AAVR displayed on the PCL microspheres with
AAV vectors.
We tested the capacity of cys-AAVR-PCL microspheres to capture
various AAV serotypes, including AAV1, -2, -3, -5, -6, -8, and -9
and AAVr3.45, by evaluating the cellular transduction of non-bound
AAV vectors (i.e., free vectors); robust interactions of AAVR with
AAV vectors would reduce free viral vectors and result in decreases
of cellular transduction by vectors in supernatant. Ten milligrams
of cys-AAVR-PCL or non-modiﬁed PCL microspheres were added
to HEK293T producer cell lysates containing each vector, followed
by a 1-h incubation. The viral binding to cys-AAVR PCL micro-
spheres was assessed in parallel as a control. Numerous proteins in
cell lysates, including viral vectors, can be non-speciﬁcally adsorbed
onto hydrophobic non-modiﬁed surfaces;37 therefore, both PCL
microsphere sets were pre-coated overnight with a surfactant (i.e.,
0.01% [v/v] Tween 20) prior to the viral binding. The supernatants
were then aspirated and transferred to fresh HEK293T cell cultures,
such that the non-bound AAV could infect HEK293T cells. Regard-
less of the AAV serotype, substantial reductions in the percentage
of GFP-expressing cells, ranging from 2.7- to 27-fold, were observed
for the supernatants from cys-AAVR-PCL compared to those in the
control non-modiﬁed microspheres (Figure 3). For example, incuba-
tion with AAV2 and AAVr3.45 vector stocks resulted in GFP
expression in 91% and 98%, respectively, of 293T cells, whereas
supernatants following the incubation of an identical dosage of
vectors with cys-AAVR-PCL microspheres resulted in 6.3% or 3.7%
GFP-positive cells. In the case of AAV9, a 2.7-fold decrease in the
transduction was observed after the viral depletion with the cys-
AAVR-PCL microspheres compared to the transduction with an
equivalent dosage of vector stock. Binding efﬁciencies to the cys-
AAVR-PCL microspheres were reproducibly signiﬁcantly higher
than that of the non-modiﬁed PCL microspheres (p < 0.05), demon-
strating the speciﬁc interactions of the AAVR adhered to PCL
microspheres with AAV vectors regardless of their serotypes.
cys-AAVR-PCL Systems for Localized and Sustained AAV
Delivery
The capacity of cys-AAVR-PCL to function as a gene delivery carrier
for in vitro transduction was initially evaluated using an electrospunMolecular Therapy: Nucleic Acids Vol. 18 December 2019 435
Figure 4. In Vitro Release Kinetics and Cellular Transduction on cys-AAVR-
PCL Fibrous Matrices
(A) Fluorescence images of viable (fluorescein diacetate [FDA], green) and dead
(propidium iodide [PI], red) HEK293T cells that were grown on cys-AAVR-PCL
matrices with or without loaded AAV2 vector. The nuclei of the cells were coun-
terstained with DAPI (blue). (B) Cellular proliferation (HEK293T cells) was measured
by a colorimetric assay (cell-counting kit-8 [CCK-8]). (C) Cumulative release profiles
of AAV2 vectors from cys-AAVR-PCL or non-modified PCL electrospun matrices.
The fluorescence intensities of Alexa 594-tagged AAV vectors were measured at
designated time points, and the cumulative releases were expressed as the ratio of
the fluorescence intensities measured at each time point to those at the last time
point (i.e., 336 h). (D) Time-dependent profiles (RLU/mg protein) of in vitro cellular
transduction by AAV2 vectors that were immobilized onto cys-AAVR-PCL or non-
modified PCL electrospun fibrous matrices. Error bars represent SDs.
Molecular Therapy: Nucleic Acidsﬁbrous formulation, rather than microspheres, due to the conve-
nience of growing cells on their relatively ﬂat surfaces. To analyze
in vitro cellular transduction, AAV2 vector encoding luciferase
(AAV2-luc) was adhered to a cys-AAVR-PCL ﬁbrous matrix by
gently agitating for 1 h followed by rinsing with PBS, and the resulting
mixture was seeded with HEK293T cells. Cellular transduction was
then monitored by quantifying luciferase expression. As controls,
AAV2-luc vectors in suspension (1  109 viral genomes [vg])
were dropped and marginally air-dried on the non-modiﬁed PCL
matrices without washing to conserve the initial viral quantities
(i.e., 1  109 vg). To our knowledge, there is no method to examine
cellular transduction proﬁles with identical viral quantities on each
surface due to their different properties (non-modiﬁed PCL versus436 Molecular Therapy: Nucleic Acids Vol. 18 December 2019cys-AAVR-PCL matrices). Instead, time-dependent, characteristic
delivery modes from each surface (e.g., rapid versus gradual in-
creases), rather than a comparison of the delivery efﬁciencies of
each system, were assessed.
Prior to analyzing the in vitro transduction, the biocompatibility of
the cys-AAVR-PCL matrices or cys-AAVR-PCL with AAV2 was
veriﬁed by the presence of high densities of live cells on their surfaces
(Figure 4A). Cellular proliferation on the cys-AAVR-PCL matrices or
cys-AAVR-PCL with AAV2 was not signiﬁcantly different from that
on tissue culture plates (Figure 4B). Next, the release kinetics of AAV
vectors from the cys-AAVR-PCL systems were examined by tagging
the AAV vectors with Alexa Fluor 594 followed by quantifying the
time-dependent ﬂuorescence intensities of the desorbed vector.
Speciﬁc interactions of cys-AAVR with AAV vectors apparently
reduced the initial burst release of vector and slowed subsequent
release from the AAVR-PCL systems (i.e., electrospun matrices or
microspheres) compared to that from the non-modiﬁed PCL (Figures
4C and S3). Furthermore, the in vitro cellular transduction proﬁles on
each matrix correlated with the delivery trends observed in the release
kinetics. That is, luciferase expression levels on the non-modiﬁed PCL
ﬁbrous matrices showed a faster onset of expression (<4 days) than
that on the cys-AAVR-PCL matrices (Figure 4D). However, the spe-
ciﬁc loading of AAV onto the cys-AAVR-PCL matrices resulted in an
apparent progressive viral release, indicated by gradually increasing
luciferase expression,20 and the levels of luciferase expression
at 10 days post-transduction were signiﬁcantly higher than those at
4 days post-transduction (Figure 4D). These results indicate that
the cys-AAVR-PCL system can serve as a serotype-independent
tool to modulate AAV delivery in a sustained manner compared to
the non-modiﬁed systems.
Next, the potential for localized in vivo gene delivery was evaluated,
and AAV9 was selected due to its muscle infectivity.3,39 As schemat-
ically illustrated in Figure 5A, 10 mg of cys-AAVR-PCL microspheres
or control non-modiﬁed PCL microspheres were added to AAV9-luc
(5  1010 vg in 30 mL, previously puriﬁed via density ultracentrifuga-
tion). After gentle mixing, the whole suspension (30 mL) containing
the same quantity (5  1010 vg) as the virus suspension was immedi-
ately injected into themouse hind limbmuscle (n = 6) without further
treatment, such as removal of non-speciﬁcally bound vector with
surfactant or removal of non-bound vector. In parallel, a puriﬁed
AAV9 vector solution (30 mL; without interacting with PCL micro-
spheres) was injected at an identical vector dosage (5  1010 vg).
The AAV9-luc solution resulted in widespread luciferase expression,
both in the hind limb as well as in the liver and heart (top panels of
Figure 5B, shown with arrows), at levels maintained for the course
of this study (Figure 5C). The injection of AAV9 mixed with non-
modiﬁed PCL microspheres resulted in a marginal increase in the
spread area of gene expression (i.e., region of interest [ROI] values
drawn along the minimum luminescence signals) relative to those ob-
tained by AAV9 delivery from cys-AAVR-PCL microspheres (Table
S1) (middle and bottom panels of Figure 5B). This increase of the
spread area, however, was not statistically signiﬁcant at any time point
Figure 5. Localized Gene Delivery by AAV9 Loaded onto cys-AAVR-PCL Microspheres
(A) Schemes depicting the delivery system. cys-AAVR-PCL microspheres (10 mg) were dispersed in each viral sample (total of 5  1010 vg; iodixanol purified), and the
resulting suspensions were intramuscularly injected into the mouse hind limb. Note that the non-modified PCL microspheres were pre-treated with Tween-20 to reduce the
non-specific binding of AAV9 to the surfaces. Without rinsing and centrifugation, the suspensions containing virus and microspheres were injected immediately after each
microsphere set was added to the suspension. (B) In vivo bioluminescence images of luciferase light signals emitted from transduced cells upon intramuscular injections of
three groups: (1) only AAV9 solution (top, n = 6), (2) AAV9 solution with non-modified PCL microspheres (middle, n = 6), and (3) AAV9 solution with cys-AAVR-PCL mi-
crospheres (bottom, n = 6). (C) Time-dependent bioluminescence intensities (p/s/cm2/sr) at 3, 7, 13, 20, 27, and 45 days. Error bars represent SDs. (D) Light signals from
several representative organs (liver, spleen, heart, kidney, and lung). (E) H&E staining of muscle tissue isolated at 20 and 40 days post-injections. Multiple H&E-stained images
were assembled to represent the whole tissue sections.
www.moleculartherapy.org(Table S1). Finally, AAV9 immobilized to cys-AAVR-PCL micro-
spheres, whose initial release rates (<4 days) were signiﬁcantly slower
than those from the non-modiﬁed PCL microspheres (Figure S3),
which resulted in gradual increases in the light signals as well as
strong light emission directly over the injection sites (bottom panels
of Figure 5B). While the slow release from the cys-AAVR-PCL
microspheres resulted in signiﬁcantly lower gene expression at
7 days than that of the AAV9 solution, stable, localized gene expres-
sion was observed at the injection site for extended time periods at
levels comparable to animals administered with soluble AAV or
AAVwith non-modiﬁed PCLmicrospheres (Figure 5C). These obser-
vations establish that the cys-AAVR-PCL materials can be utilized to
mediate localized and sustained gene delivery at deﬁned sites.At 20 days post-injection, several organs, including the heart,
liver, spleen, lung, and kidney, were harvested, and the luciferase
signals from each organ were examined to further characterize
off-target gene delivery. For animals injected with vector solution,
high luciferase expression was observed in the liver and heart;
however, in contrast, no signal was detected from any organ
when AAV9 was administered in complex with cys-AAVR-PCL
microspheres (Figure 5D). Similarly, in the absence of a step
such as surfactant rinsing to remove non-speciﬁcally bound
vector, animals treated with non-modiﬁed PCL microspheres
also showed no expression in the liver or heart. Off-target gene
delivery was examined by quantifying the levels of luminescence
emitted from individual organs (Figure S4), and signiﬁcantlyMolecular Therapy: Nucleic Acids Vol. 18 December 2019 437
Figure 6. Spatially Patterned Gene Delivery by AAV Loaded onto cys-AAVR-PCL Matrices
(A) Schemes depicting the delivery system. AAV2-luc vectors (3 1010 vg) were adsorbed onto the cys-AAVR-PCL electrospunmatrices with a spatial pattern (i.e., V pattern),
which were subcutaneously implanted onto the back of mice. Non-modified PCL matrices were pre-treated with Tween-20 to reduce AAV2 non-specific binding to the
surfaces. (B) In vivo bioluminescence images of luciferase light signals over the implanted matrices with spatial patterns: AAV2 with non-modified PCL matrix (top, n = 6) and
AAV2 with cys-AAVR-PCL matrix (bottom, n = 6). The dotted line indicates the location of implanted matrices. (C) Bioluminescence intensities (p/sec/cm2/sr) at designated
time points (i.e., 3, 7, 10, and 13 days). The asterisk (*) indicates significant differences at identical time points. Error bars represent SDs. (D) H&E staining of tissue isolated at
45 days post-implantation. The letters “T” and “M” indicate surrounding tissues and matrices, respectively. The dotted regions correspond to the regions shown with high
magnification.
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compared to the level observed in negative controls (i.e., organs
of non-infected animals) was detected in the muscle, heart, and
liver of animals infected by vectors in solution. In contrast, the
levels observed for AAV9/cys-AAVR-PCL from the majority of or-
gans except for the injected muscle were similar to the ones for
negative controls.
Mild immune inﬁltration was observed around the cys-AAVR-PCL
microspheres or non-modiﬁed PCL microspheres in tissue sections
obtained 20 days post-injection (Figure 5E). The majority of in-
ﬂammatory cells regressed at later stages (40 days post-injection;
Figure 5E), consistent with our observation that tumor necrosis
factor-alpha (TNF-a) levels in plasma 45 days post-injection per-
sisted at a basal level (Figure S5). Additionally, body weights of
all animals showed no signiﬁcant differences (Figure S6), further
demonstrating the biocompatibility of the cys-AAVR-PCL-medi-
ated AAV delivery.438 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Finally, the capacity of cys-AAVR-PCL systems to mediate another
localized gene delivery mode (spatially patterned gene delivery) was
investigated by subcutaneously implanting the composite of AAV2-
luc/cys-AAVR-PCL electrospun matrices (or AAV2-luc/non-modi-
ﬁed PCL matrices; n = 6) whose structural exteriors were conﬁned
into a speciﬁc shape (i.e., V pattern). As shown in Figure 6A,
electrospun matrices (cys-AAVR-PCL or non-modiﬁed PCL) with
a V pattern were manually formulated, and AAV2-luc vectors were
immobilized on each surfactant-treated electrospun matrix. The re-
sulting composites, which were vigorously rinsed with PBS prior to
implantation to remove weakly-bound vector, were subcutaneously
implanted into the back of mice, and the ability of cys-AAVR-PCL
to mediate deﬁned patterns of vector transduction corresponding to
the shape of the original implanted matrices (i.e., V shape) was exam-
ined. Luciferase signals with spatial patterns gradually appeared as
time elapsed, whereas the non-modiﬁed PCL matrices containing
non-speciﬁcally bound AAV2-luc with low quantities (possibly due
to surfactant rinsing) induced low levels of light signals without
www.moleculartherapy.orgconﬁned patterns (Figure 6B). Importantly, as consistently observed
in the intramuscular injections (Figure 5), apparent levels of light
emission from the cys-AAVR-PCL electrospun matrices were de-
tected progressively (>6 days post-transplantation) (Figures 6B and
6C), resulting in levels substantially higher than for non-modiﬁed
PCL. For either of the delivery sets, no signiﬁcant recruitment of in-
ﬂammatory cells was observed around the implanted matrices
(Figure 6D), further verifying the biocompatible properties of the
electrospun cys-AAVR-PCL matrices releasing AAV vectors. In
sum, the biomaterial gene delivery of an afﬁnity-immobilized vector
offers a broad and facile strategy for localized and sustained gene
delivery.
DISCUSSION
The AAV-binding domain of the multi-AAVR was successfully con-
jugated to the biodegradable and biocompatible PCL materials (i.e.,
cys-AAVR-PCL), thereby allowing them to physically interface with
AAV vectors, nearly regardless of serotype. This universal feature
of the cys-AAVR-PCL clearly distinguishes it from other recent
biomaterial-mediated gene delivery constructs by us and others,
which are complicated by the need to design new biomaterial immo-
bilization strategies for each serotype. The versatile AAVR-PCL
composite reported here simultaneously addressees two challenges
associated with AAV-mediated gene delivery: (1) serotype-indepen-
dent AAV capture/binding with a single system and (2) localized/
sustained delivery of AAV vector. No further decoration or modiﬁca-
tion of the biomaterials is required except for AAVR conjugation.
Additionally, almost all naturally occurring AAV serotypes can be
immobilized onto the AAVR system without chemical or genetic
modiﬁcations, thereby conserving their inherent infectious proper-
ties. Moreover, there are no limitations in the biomaterial structures
to functionalize their surfaces since the AAVR conjugation can be
conducted once their exteriors are completely constructed via desired
processes. Thus, the AAV serotype-independent platform system us-
ing AAVR can be employed for a broad range of AAV applications,
from gene therapy and regenerative medicine to fundamental biolog-
ical studies.
The building block material (e.g., PCL in this study) can be
substituted, in principle, with any material with functional groups
(e.g., dextran and Sepharose) capable of speciﬁcally reacting with
thiols on the cys-AAVR (e.g., maleimide with thiols). Thus, the cys-
AAVR-PCL system can be straightforwardly translated into any
biocompatible material depending on a given gene therapy or tissue
engineering application. It is also likely on this or other materials
that vector capture and release can be modulated by adjusting the sys-
tems’ spatial geometry or AAVR quantities/distribution on the sur-
faces. Furthermore, each AAV serotype differentially interacts with
PKD domains 1–5;40 thus, it is conceivable that the selection or order
of the PKD domains integrated onto a material could enable the tun-
ing of the AAV binding and release proﬁles as well as enhance the
capture of a lower afﬁnity serotype, such as AAV432 (Figure 1B).
Importantly, decorating material surfaces with PKD 1 and PKD 2,
which have been recently known as key domains capable of specif-ically interacting with AAV vectors,41 can be an alternative method
to enhance the speciﬁcity of the cys-AAVR system to various AAV
serotypes and potentially improve its AAV binding capacity. Further
optimization of the cys-AAVR system to facilitate scale-up will,
of course, be needed for successful translation toward human
application.
Localized/spatially patterned AAV delivery technology can enhance
the safety and efﬁcacy for certain applications because off-target
localization can elicit immune responses, dilute therapeutic efﬁcacy
into irrelevant organs/tissues,42 or result in transgene toxicity in
off-target cells. While decorating the AAV capsid with cell surface
receptors/ligands to alter its tissue/organ tropism42 or regulating
transcription by carrying tissue-speciﬁc promoters43,44 has been
extensively proposed to limit off-target localization and expression,
in general, even after local administration, it is challenging to prevent
vector leakage into the circulation, resulting in the systemic spread of
AAV capsid antigen and transgene. For example, upon intramuscular
injection of AAV9 suspensions, we observed strong gene expression
in non-targeted organs such as the heart and liver (Figure 5D). Local-
ized or even spatially patterned gene delivery can better control
delivery localization for gene therapy and regenerative medicine
applications.45 Biomaterial systems that can create spatially patterned
gene delivery would be beneﬁcial for mimicking spatially organized
tissue structures in the body46 (e.g., aligned tendon and concentric
shapes of bone) or stimulating stem cells to induce multi-lineage
differentiation within a conﬁned region,47 particularly for tissue
engineering applications. Because PCL and other functionalizable
materials can be generated in a broad range of formats and geome-
tries, the system can be further adapted for different modes of delivery
and release, ranging from microsphere suspensions and elution from
solid three-dimensional polymeric implants to incorporation within
hydrogels, for gene therapy and tissue engineering applications.
Capturing AAV vectors without their chemical or genetic modiﬁca-
tions followed by injection of themicrosphere-adsorbed vector in vivo
to enable the tissue to “elute” the vector resulted in strong, localized
gene expression (Figures 5 and 6). That is, regardless of the viral
preparation conditions, simply including the cys-AAVR-biomaterial
into vector suspensions can be a highly efﬁcient process to selectively
capture AAV and subsequently induce localized gene delivery in vivo.
This method substantially reduces the number of complex viral prep-
aration steps prior to vector injections, which may be beneﬁcial for
increasing the viral yield and reducing product costs.
Conclusions
The cys-AAVR-PCL system is the ﬁrst to successfully apply the funda-
mental discovery of AAVR toward novel applications: in this case, the
controlled, sustained, and patterned delivery of AAV. The potential of
combining viral vectors with engineered biomaterials, which can
potentially overcome the limitations associated with current AAV-
mediated gene delivery approaches (e.g., off-target gene delivery
and the diverse viral binding methods, which differ based on the
AAV serotype), was demonstrated in this study. AAVR-displayingMolecular Therapy: Nucleic Acids Vol. 18 December 2019 439
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controlled isolation and delivery of all AAV serotypes, thereby
broadening their potential applications from gene therapy to regener-
ative medicine.
MATERIALS AND METHODS
Production of Cysteine-Modified, Water-Soluble AAVR
Recombinant water-soluble AAVR was expressed in Rosetta(DE3)
E. coli carrying an expression plasmid (pETDuet-1; Novagen, Madi-
son, WI, USA) that encoded a partial sequence of AAVR (i.e., PKD
1–5), which had been ampliﬁed from a KIAA0319L cDNA clone
(clone ID 3843301; GE Dharmacon, Lafayette, CO, USA) by using
the following primers: 50- GCTAGGGATCCAGGCGGTGGCGG
TAGCTGTTGCTGTGGCGGTGGCGGTAGCGGCGGTGGCGGT
AGCGTATCTGCTGGAGAGAGTGTCCAGATAACC-30 and 50-
GCTAGGCGGCCGCCTACAGGTTGTTTTTCCTGGG-30. The re-
combinant AAVR proteins that contained histidine and cysteine
tags at the N terminus, which were referred to as cys-AAVR, were
extracted from the E. coli and harvested by using nickel-charged
afﬁnity beads (Ni-nitrilotriacetic acid [NTA]; QIAGEN, Hilden,
Germany) according to the manufacturer’s guidelines.
Characterization of cys-AAVR
The production of cys-AAVR protein was veriﬁed by SDS-PAGE,
followed by Coomassie staining (Coomassie Brilliant Blue R-250,
BioRad Laboratories, Hercules, CA, USA). The quantity of recombi-
nant cys-AAVR protein was assessed by using a Bicinchoninic Acid
Protein (BCA) assay kit (Thermo Fisher Scientiﬁc, Waltham, MA,
USA). The functionality of cys-AAVR to broadly interact with
various AAV serotypes was examined by monitoring the reductions
in the transduction efﬁciencies of AAV vectors after their association
with cys-AAVR (0.2 mM). A cell line (HEK293T; 2  104) known to
be permissive to the majority of wild-type AAV serotypes (i.e.,
AAV1, -2, -3, -4, -5, -6, -8, and -9 and AAVr3.45) was seeded on
48-well plates 1 day prior to the viral infection. At 48 h post-infection,
the percentages of GFP-expressing cells were measured using a ﬂow
cytometer at the Yonsei University College of Medicine Medical
Research Center (LSR2, BD Bioscience, San Jose, CA, USA).
Fabrication of Polymeric Templates to Anchor cys-AAVR
Biodegradable PCL (80,000 Da, Sigma-Aldrich, St. Louis, MO, USA)
polymers were formulated into two different structures: microspheres
and nanoﬁbrous matrices. The PCL microspheres were fabricated by
using an water-oil single emulsion technique.34 Brieﬂy, a large-scale
process was employed to prepare large numbers of microspheres:
50mL of 10% (w/v) PCL dissolved in chloroform (Duksan Chemicals,
Ansan, Korea) was transferred into 1 L of 2% (w/v) aqueous polyvi-
nylalcohol (PVA, Mn = 20,000–30,000 Da; Sigma-Aldrich) solution,
and the water-oil phase was emulsiﬁed using a homogenizer
(HMZ-20N, Poong Lim, Seoul, Korea) for 30 s. The emulsion was
magnetically stirred for an additional 2 days to completely
evaporate the chloroform (Duksan, Seoul, Korea) from the solidiﬁed
PCL microspheres; then, these microspheres were settled using a
high-speed centrifuge (MEGA 17R, Hanil, Seoul, Korea), vigorously440 Molecular Therapy: Nucleic Acids Vol. 18 December 2019washed ﬁve times with distilled water, and ﬁltered through a sieve
(diameter = 40 mm; SPL Life Science, Pocheon, Korea) to remove large
microspheres. Finally, the PCL microspheres were lyophilized and
stored in a desiccator until use. The nanoﬁbrous PCL matrices were
fabricated by using an electrospinning technique that has been
previously described.34,48 Brieﬂy, 15% (w/v) PCL dissolved in a
mixture (1:1, v/v) of chloroform (Duksan) and dimethylformamide
(DMF; Duksan) was electrospun using electrospinning equipment
(ESR-100, NanoNC, Seoul, Korea) under 14-kV voltage and using a
15-cm tip-to-collector distance. The ﬂat PCL ﬁbers were collected
for 90 min on grounded ﬂat aluminum foil and stored in a desiccator
until use.
Surface Modification of PCL Templates with cys-AAVR
The surfaces of the PCL structures were decorated with cys-AAVR
proteins via a click-chemistry methodology. Brieﬂy, the PCL struc-
tures (i.e., microspheres and electrospun ﬁbers) were immersed
in 30% HDA (Sigma-Aldrich) dissolved in isopropanol (Sigma-
Aldrich) and gently agitated for 3 h at room temperature to create
amines on the PCL surfaces (PCL-NH2). Subsequently, the
aminolyzed PCL surfaces were washed three times with PBS, trans-
ferred to Sulfo-SMCC (4 mg/mL; Thermo Fisher Scientiﬁc) in PBS
solution to create maleimide-displaying PCL surfaces (PCL-click),
and kept in a shaking incubator for 1 h. The resulting PCL-click
surfaces were rinsed three times with PBS and gently agitated with
0.4 mg/mL cys-AAVR in PBS solution at 4C overnight. After being
washed three times with PBS, the cys-AAVR-conjugated surfaces
(cys-AAVR-PCL) were immediately used for anchoring AAV
vectors. All the solvents and solutions that were used for conjugating
cys-AAVR onto the PCL surfaces were ﬁltered through 0.22 mm
syringe ﬁlters to assure their sterilization.
Characterization of cys-AAVR-Conjugated PCL Surfaces
The presence of the chemical moieties generated from the series of
reactions was veriﬁed by Fourier transform infrared (FT-IR) spectros-
copy (Spectrum 100, Perkin Elmer, Waltham, MA, USA). The
aminolysis of the PCL surfaces was examined by quantifying the
number of amines that were displayed on the PCL surfaces by ninhy-
drin assay, as described elsewhere.49 Brieﬂy, the aminolyzed surface
was immersed in ninhydrin (Sigma-Aldrich) solution (1 M in isopro-
panol) and incubated at 90C for 15 min. Once the residual solvent
was completely evaporated by cooling the PCL surfaces, 1,4-dioxane
(Sigma-Aldrich) was added to dissolve the aminolyzed materials, and
isopropanol was included to produce the blue product. The absor-
bance of the ﬁnal solution at 560 nm was measured using a spectro-
photometer (Nanodrop 2000, Thermo Fisher Scientiﬁc) to quantify
the presence of amines on the PCL surfaces, and the concentration
of the amines was calculated based on a standard curve that was
created with serially diluted solutions of HDA. The conjugation of
cys-AAVR with the PCL microspheres was visualized by labeling
the cys-AAVR with Alexa Fluor 594 (Thermo Fisher Scientiﬁc) and
imaging the ﬂuorescence using a confocal laser scanning microscope
(CLSM; LSM 700, Carl Zeiss, Thornwood, NY, USA). The surface
hydrophilicity of the cys-AAVR-PCL systems was examined by
www.moleculartherapy.orgmeasuring the water contact angles (CAM101, KSV Instruments,
Espoo, Finland) on the electrospun ﬁbrous matrices.
Production of AAV Vectors
Eight naturally occurring AAV serotypes, AAV1, -2, 3-, -4, -5, -6, -8,
and -9 and an AAV derivative, AAVr3.45, were designed to encode
the GFP or luciferase (luc) genes driven by a cytomegalovirus
(CMV) promoter and were packaged by a calcium phosphate tran-
sient transfection method using an equal amount of three plasmids
(17 mg each):17,50 AAV helper plasmids, which are required for gener-
ating each capsid structure (i.e., pXX1, -2, -3, -4, -5, -6, -8, and -9 and
pAAVr3.45); plasmids carrying reporter genes (GFP, luc) that are
ﬂanked by inverted terminal repeats (ITRs); and an adenoviral helper
plasmid (pHelper; Stratagene, La Jolla, CA, USA). These plasmids
were electrostatically complexed with calcium cations to transfect
AAV293 cells (Stratagene). At 48 h post-transfection, the cells were
lysed by a freeze-thawing procedure three times, and the lysed solu-
tion that contained the viral vectors was treated with benzonase
nuclease (Sigma-Aldrich) to remove fragments of cellular genomes.
The resulting AAV vectors were puriﬁed by a density gradient
method that used iodixanol (OptiPrep, Axis-Shield, Oslo, Norway)
and ultracentrifugation (360,000  g; Type 100 Ti rotor, Beckman
Coulter, Brea, CA, USA) for 2 h at 18C. Following these steps,
the buffers of each puriﬁed viral sample were replaced with 1
PBS-0.01% (v/v) Tween-20 (Sigma-Aldrich) using Amicon tubes
(Ultra-15; 10 000 MWCO, Millipore, Billerica, MA, USA) according
to the manufacturer’s protocol. The genomic DNA of all the viral
samples that resisted a deoxyribonuclease (DNase I; Thermo Fisher
Scientiﬁc) was quantiﬁed by qPCR (Mini Opticon, Bio-Rad, Hercules,
CA, USA) using SYBR Green master mix (Thermo Fisher Scientiﬁc).
In Vitro Characterization of AAV Delivery from cys-AAVR-
Conjugated PCL Surfaces
The in vitro transduction efﬁciency of AAV vectors from the cys-
AAVR-PCL structures was characterized by measuring the luciferase
signal within the transduced cells grown on the PCL electrospun
matrices. To examine the deviations of the cellular transduction on
the different surfaces, the initial viral quantities on each surface were
ﬁxed similarly. The cys-AAVR-PCL electrospun ﬁbers were incubated
with AAV2 (1 109 vg/matrix) that encoded ﬁreﬂy luciferase (AAV2-
luc) for 1 h under gentle shaking. The cellular transduction on the
non-modiﬁed PCL matrices that contained the adsorbed AAV2 was
employed as a control; AAV2 vectors (1  109 vg/matrix) were drop-
ped and marginally air-dried on the non-modiﬁed PCL matrices
without rinsing with PBS to adsorb viral quantities similar to those
compared on the cys-AAVR-PCL surfaces. Subsequently, HEK293T
cells (1  104 cells/matrix) were seeded onto each surface that con-
tained viral vectors. The supernatant in each well was replaced with
fresh medium at 3, 6, 9, and 12 days post-culture. At 4, 7, 10, and
13 days post-transduction, the transduced cells on each PCL surface
were lysed using a luciferase assay kit (Promega, Madison, WI,
USA), and the expression levels of the luciferase that were cumula-
tively emitted from a cell population were measured using a luminom-
eter (LB96P, EG & G, Berthold, Germany). The results were normal-ized to the total quantity of the proteins that were expressed from the
cells, which was determined using a bicinchoninc acid protein (BCA)
assay kit (Thermo Fisher Scientiﬁc). The live/dead cells on the cys-
AAVR-PCL ﬁbrous matrices were stained by ﬂuorescein diacetate
(FDA; Sigma-Aldrich)/propidium iodide (PI; Sigma-Aldrich) and
examined using a confocal laser scanning microscope (CLSM; Carl
Zeiss) to evaluate the biocompatibility of the cys-AAVR-PCLmatrices
as a cell culture system. The quantitative analysis on the proliferation
of HEK293T cells on the cys-AAVR-PCL matrices was conducted us-
ing a CCK-8 (Cell Counting Kit-8; Dojindo Lab, Kumamoto, Japan)
assay according to the manufacturer’s guidance.
In VivoGene Delivery by AAV from cys-AAVR-PCLMicrospheres
The localized and sustained AAV delivery from the cys-AAVR-PCL
systems was investigated by monitoring the luciferase expression
proﬁles both spatially and temporally in mice following intramus-
cular injection. Brieﬂy, the cys-AAVR-PCL microspheres (10 mg)
were placed in a PBS solution that contained puriﬁed AAV9-luc vec-
tors (5  1010 vg), and the resulting suspension (10 mg PCL/mouse)
was injected into the left hind limb of a mouse (ICR mouse, Orient
Bio, Seongnam, Korea) using a syringe (1 mL; Korea Vaccine, Seoul,
Korea). At different times after the vector administration, luciferin
(10 mg/mL in PBS; 150 mL/g mouse, Promega) was intraperitoneally
injected into each mouse, and the time-dependent extent and
localization of the luciferase expression were visualized using an
IVIS Spectrum imaging system (PerkinElmer, Waltham, MA,
USA). Additionally, the muscle tissues were dissected and sectioned
using a cryostat microtome (Leica CM 1850, Leica Biosystems,
Nussloch, Germany) and stained with H&E (Sigma-Aldrich) to qual-
itatively analyze the injected tissue. For analyzing the patterned gene
delivery using the cys-AAVR-PCL systems, AAV2-luc vectors (3 
1010 vg) were loaded onto either cys-AAVR-PCL or non-modiﬁed
PCL electrospun matrices with a V pattern (width  length = 2 
1 cm); the resulting composites were subcutaneously implanted on
the back of mice. The shape of the luciferase signals over the im-
plantedmatrices was qualitatively examined at designated time points
(6, 10, 20, and 45 days) to determine the time-dependent extent of the
patterned gene delivery. Luciferase expression from individual organs
was quantiﬁed by using a luciferase assay kit (Promega). Brieﬂy,
animals were sacriﬁced 20 days post-injection, and individual organs,
including heart, liver, spleen, lung, and muscles, were isolated and
processed using a homogenizer (Precellys 24, Bertin Technologies,
Villeubanne, France). Subsequently, the homogenized tissues were
immersed in lysis buffer (Promega) prior to measuring the lumines-
cence using a luminometer (LB96P). The levels of luminescence
(RLU) were normalized to the amount of protein collected from
each organ (i.e., RLU/mg protein). In vivo inﬂammatory responses
after administrating AAV9 vectors into hindlimb muscle were
analyzed by TNF-a in mouse plasma 45 days post-injection. Brieﬂy,
blood samples of mice treated with each delivery set were collected
at 45 days post-injection and immediately transferred into a K2-
EDTA microtube (BD Microtainer, BD Biosciences) to prevent
coagulation. After centrifugation, separated plasma was harvested,
and 100-fold diluted plasma was analyzed by a TNF-a ELISA kitMolecular Therapy: Nucleic Acids Vol. 18 December 2019 441
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manufacturer’s protocols. The quantity of TNF-a was normalized
to that of proteins collected from the plasma (pg/mg protein), which
was measured using a BCA assay kit (Thermo Fisher Scientiﬁc). All of
the animal experimental procedures were performed in accordance
with the guidelines and under the approval of the Institutional
Animal Care and Use Committee of Yonsei University College of
Medicine (no. 2016-0092).
Characterization of Viral Release Kinetics from cys-AAVR-PCL
Systems
The kinetics of the AAV releases from the cys-AAVR-PCL systems
were examined by measuring the ﬂuorescence intensities of Alexa
Fluor 594 tagged on the AAV vectors, which were released to the
supernatant from cys-AAVR-PCL or non-modiﬁed PCL electrospun
matrices. Alexa Fluor 594-tagged AAV2 vectors (1  109 vg/matrix)
were incubated with PCL matrices for 30 min at room temperature
and rinsed gently with PBS. To adsorb sufﬁcient viral quantities,
AAV2 vectors were marginally air-dried on the non-modiﬁed PCL
matrices, and their time-dependent release proﬁles were examined
by detecting the ﬂuorescence intensities of Alex Fluor 594, which
was tagged onto AAV2 vectors. The supernatant in each well was
collected at 0, 1, 3, 12, 24, 48, 96, 168, 240, and 336 h post-incubation
and replaced with fresh PBS. The ﬂuorescence intensities of Alexa
Fluor 594 were measured using Nanodrop, and the cumulative viral
releases were determined as the ratio of the ﬂuorescence intensities
measured at designated time points to those quantiﬁed at the ﬁnal
time point (i.e., 336 h).
Statistical Analysis
All statistical analyses were performed via one-way ANOVA, fol-
lowed by Dunnett’s post hoc test or Student’s t test using SPSS 25.0
software (IBM, New York, NY, USA). All experimental sets were con-
ducted at least in triplicate and are presented as averaged values with
SDs.
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